Vote in Free Arena

News··1 min read·Data updated automatically

Boltz raises $110M Series A to accelerate AI‑driven small‑molecule research

The medical AI startup Boltz secured $110 million led by Bessemer, expanding compute and hiring to boost its BoltzMol‑1 and BoltzProt‑1 models.

Boltz PBC announced a $110 million Series A round on 19 November 2026, with Bessemer Venture Partners as lead investor.

Boltz’s AI models, BoltzMol‑1 and BoltzProt‑1, generate binding‑affinity data and protein designs, reducing the number of molecules researchers must test.

Since their launch in June, token usage for the models has grown 50‑fold, and six of the world’s 20 largest pharma companies are customers, including Pfizer, GSK, Takeda and BMS.

The new funding will support additional compute infrastructure, data acquisition, and team expansion, aiming to keep pace with AI leaders such as Anthropic and OpenAI.

What it means for you

The investment signals growing confidence in AI tools that cut drug‑discovery cycles, offering faster, cheaper insights for pharmaceutical research. For AI users, especially those seeking free or local models, Boltz’s token‑based API shows how specialized AI services can scale quickly, highlighting the importance of compute resources and data in advancing domain‑specific models.

Sources

Written automatically from the sources above, then checked by our code: every number and name must appear in them, and no sentence may copy a source. Spotted a mistake? Report it.

Free leaderboard

Which AI can you use for free today?

Every free AI model, ranked by blind human votes, with the memory and speed it needs on your own GPU.

Open the leaderboard →

Share this page:XLinkedInRedditWhatsApp

Press / or Ctrl+K to search from any page.